Content |
Assets
History
2022
Purchase of Horizon Therapeutics for $28 billion
On December 12, 2022, Amgen, the world's largest biopharmaceutical corporation, announced an agreement to buy Horizon Therapeutics, which specializes in drugs for rare diseases. The transaction amount will be approximately $27.8 billion. Read more here.
Amgen bought a manufacturer of drugs for the treatment of a rare disease of blood vessels for $3.7 billion
In early August 2022, Amgen and the biopharmaceutical ChemoCentryx, which specializes in the development of oral therapeutic drugs for autoimmune diseases, inflammatory disorders and cancer, entered into a final agreement under which Amgen will acquire ChemoCentryx for $52 per share. The transaction value is $3.7 billion. Read more here
2021: $1.9 billion purchase of stomach cancer drug developer Five Prime Therapeutics
In early March 2021, Amgen bought the developer of the drug for the treatment of stomach cancer Five Prime Therapeutics for $1.9 billion. Under the agreement, Amgen will pay $38 per Five Prime share, well above the normal market price ($21.26). The deal is expected to close by the end of the second quarter of 2021. Read more here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |